Trend Press Wire

Hemophilia Market is Heading Up 17 Billion US$ By 2026

Press release   •   Aug 01, 2019 03:50 EDT

According to Acumen Research and Consulting, The global Hemophilia Market Size is anticipated to around US$ 17 billion by 2026. The market is anticipated to grow at a CAGR of 5.3% from 2018 to 2026.

Acumen Research and Consulting has recently published a research report on the Hemophilia Market for the forecast period of 2018 to 2026, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Hemophilia Market offers an extensive analysis of how the postoperative pain therapeutics landscape would evolve through 2026.

The research study on the Hemophilia Market analyzes key drivers upholding product sales and prominent trends shaping the growth of the market. The research study not only focuses on the latent opportunities for the key stakeholders of the market, but also sheds light on the notable developments and future scope for innovation in the landscape.

The report starts off with a quick executive summary, wherein, key takeaways have been highlighted for the readers to have a sneak peak at the key market segments. The research study by ARC on the market also talks about the macroeconomic and microeconomic factors having deep-rooted influences on global market growth. The research study on the Hemophilia Market also offers a regional analysis, wherein, demand across every region has been comprehensively analyzed.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1239

The report also analyzes the Hemophilia Market on the basis of various segments, with drug type being a prominent one. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Market Segmentation:

Market By Type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Market By Treatment

  • On-demand
  • Prophylaxis

Market By Therapy

  • Replacement Therapy
  • Gene Therapy

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

Considering the demand for Hemophilia, the North America region is dominating the hemophilia market in 2018. The North America region is predicted to continue its dominance over the end of the forecast period by holding the share of more 35%. The increasing inclination toward treatment of prophylaxis is expected to be the key factordriving the growth in this region.

  • According to a global survey conducted by WHF (World Federation of Hemophilia)in 2015, approximately 63.0% of the patients in the U.S. have opted for prophylaxis treatment. The adoption of such treatment options is resulting in the acceleration of the market.

Among the other regions, the Asia-Pacific region is anticipated to witness the substantial growth over the forecast period by registering the highest CAGR growth. Increasing awareness about hemophilia among the emerging countries including India, Indonesia, Malaysia, Japan, and others is expected to boost the market growth. In addition, the increasing disposable income backed by the advancements in the medicinal treatments such as the use of therapies for the treatment of hemophilia disorder is fuelling the demand for hemophilia.

Market Participants / Key Players:

The hemophilia market is highly dominated by leading players as it is a rare disorder and no accurate treatment is present for this disorder. Some of the key players in this industry include Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., and others.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Research Methodology

The report on the Hemophilia Market is based on an extensive and meticulous bottom up approach, which was used to determine the market size.

In the primary phase of the research methodology focus on, key stakeholders, including CEOs, presidents, vice presidents, chief medical officers, and product/sales/marketing managers were interviewed for the purpose of garnering unique insights into the dynamics of the market.

VIEW FULL RESEARCH REPORT@ https://www.acumenresearchandconsulting.com/hemophilia-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemophilia
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemophilia Market By Type
1.2.2.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemophilia Market Revenue Share By Type in 2017
1.2.2.3. Hemophilia A
1.2.2.4. Hemophilia B
1.2.2.5. Hemophilia C
1.2.2.6. Others
1.2.3. Hemophilia Market By Treatment
1.2.3.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Treatment (2015-2026)
1.2.3.2. On-demand
1.2.3.3. Prophylaxis
1.2.3.4. Others
1.2.4. Hemophilia Market By Therapy
1.2.4.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.4.2. Replacement Therapy
1.2.4.3. Gene Therapy
1.2.4.4. Others
1.2.5. Hemophilia Market by Geography
1.2.5.1. Global Hemophilia Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemophilia Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemophilia Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemophilia Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Hemophilia Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemophilia Major Manufacturers in 2017

CHAPTER 4. HEMOPHILIA MARKET BY TYPE

4.1. Global Hemophilia Revenue By Type
4.2. Hemophilia A
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Hemophilia B
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Hemophilia C
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Other
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOPHILIA MARKET BY TREATMENT

5.1. Global Hemophilia Revenue By Treatment
5.2. On-demand
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Prophylaxis
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOPHILIA MARKET BY THERAPY

6.1. Global Hemophilia Revenue By Therapy
6.2. Replacement Therapy
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Gene Therapy
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOPHILIA MARKET BY COUNTRY

7.1. North America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemophilia Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOPHILIA MARKET BY COUNTRY

8.1. Europe Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOPHILIA MARKET BY COUNTRY

9.1. Asia-Pacific Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOPHILIA MARKET BY COUNTRY

10.1. Latin America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOPHILIA MARKET BY COUNTRY

11.1. Middle East Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOPHILIA MARKET BY COUNTRY

12.1. Africa Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Baxalta
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. CSL Behring
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bayer Healthcare
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. BioMarin Pharmaceutical, Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Biogen
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Chugai Pharmaceutical Co.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Novo Nordisk
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Shire Plc.
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1239

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.